incapable of losing weight or exercising, you have worse concerns
than being possibly pre-diabetic.
I love how you always take the most extreme cases you can find
(unable to exercise and lose weight) and extrapolate it to the
most common problem faced by health care.
Two new classes of diabetes drugs are having trouble in tests, leaving doctors treating the epidemic in something approaching despair.
The leading Glucagon-like peptide-1 (GLP-1) drug, Byetta, has been linked to the deaths of two people from pancreatitis.
This comes just as its maker, Amylin Pharmaceuticals, was preparing to deliver a timed-release version to the market, a weekly pill to take the place of twice-daily injections.
The news puts those plans in doubt, since the drug’s effect can’t be “turned off” if a pancreatic problem develops.
A second new class of drug, protease dipeptidyl peptidase (DPP-IV), acts to increase the effectiveness of naturally-occurring GLP-1, but its safety and efficacy is not fully established, especially with long-term use.
Given the problems with GLP-1s, expect enormous reluctance to accept such results at face value. This is bad news for DPP-IV drugs like Januvia, which is taken as a daily pill.
But it’s worse news for patients. Those with advanced diabetes have concerns about drugs they might take. Those with prediabetes face the fact there are few drugs for them at all. That number was estimated at 12 million in 2003.
The standard protocol for prediabetes thus remains weight loss and exercise. The oldest pill in the doctor’s bag, metformin, is your only choice if you can’t follow that advice.
Sorry, no miracles today.
